Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06575192 · ClinicalTrials.gov registry record · Phase 3

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

A Phase 3 study of Breast Reconstruction, sponsored by AbbVie.

Recruiting
Registry status
Phase 3
Development phase
783
Enrollment target
20
Study locations

NCT06575192 is a Phase 3 study of Breast Reconstruction that is actively recruiting participants, run by AbbVie. The registered enrollment target is 783 participants, above the 350-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06575192, a Phase 3 study of Breast Reconstruction, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 3
Development phase
783 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.

Conditions Studied

Breast Reconstruction

Interventions

  • OTHER No Intervention
  • DEVICE ARTIA Reconstructive Tissue Matrix

Study Locations (20)

California

  • Cedars-Sinai Medical Center /ID# 268326 - Los Angeles
  • UC Irvine Medical Center /ID# 267428 - Orange
  • Stanford University Medical Center CTRU - 800 Welch Road /ID# 264196 - Palo Alto
  • South Bay Plastic Surgeons /ID# 264192 - Torrance

Illinois

  • Rush University Medical Center /ID# 275935 - Chicago
  • Endeavor Health /ID# 266302 - Northbrook

New York

  • Northwell Health Clinical Trials Office /ID# 268076 - Lake Success
  • NYU Langone Medical Center /ID# 265621 - New York

Tennessee

  • Erlanger Health System /ID# 266608 - Chattanooga
  • East Tennessee State University /ID# 264321 - Johnson City

Colorado

  • University Of Colorado - Anschutz Medical Campus /ID# 268627 - Aurora

Florida

  • University of Florida College of Medicine /ID# 267485 - Gainesville

Maryland

  • Johns Hopkins Hospital /ID# 265917 - Baltimore

Missouri

  • Washington University School of Medicine - St. Louis /ID# 264029 - St Louis

Trial Details

FieldValue
Enrollment Target 783 participants
Start Date 2024-11-05
Est. Completion 2029-12
Phase Phase 3

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06575192

The ClinicalTrials.gov registry entry for NCT06575192 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 783 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 350-participant average among 18 other Breast Reconstruction trials with a reported enrollment target (124% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Reconstruction appearing as the primary indexed condition, and to 2 interventions - of which No Intervention is the first listed.

NCT06575192 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Illinois, New York.

Frequently Asked Questions

What is clinical trial NCT06575192 about?

NCT06575192 is a clinical study titled "Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants". The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.

What is the current status of trial NCT06575192?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 783 participants. The study started on 2024-11-05. Estimated completion is 2029-12.

What conditions does trial NCT06575192 study?

This clinical trial studies the following conditions: Breast Reconstruction.

What interventions are being tested in trial NCT06575192?

The interventions under investigation include: No Intervention (OTHER), ARTIA Reconstructive Tissue Matrix (DEVICE).

Who is sponsoring clinical trial NCT06575192?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06575192 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Reconstruction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Reconstruction

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.